• email
  • rss
  • twitter
  • facebook
  • linkedin
  • News
  • Investors
  • Contact

Ceapro Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Quality Management System
    • Sustainability
  • Technologies
    • Overview
    • Ethanol Fractionation Processes
    • Pressurized Gas Expanded (PGX) Technology
    • Chromatography Purification
    • Intellectual Property
    • Scientific Publications
  • Pipeline
    • Overview
    • Oat Beta Glucan
    • Avenanthramides
    • Product Brochures
  • Cosmeceuticals
    • Overview
  • Nutraceuticals
    • Overview
    • Oat Beta Glucan
    • Avenanthramides
  • Business Development
    • Overview
    • Partners
  • News
  • Investors
  • Contact
  • Home
  • Investors
  • News / Events
  • Press Releases
Navigation
  • Overview
  • News / Events
    • Press Releases
    • Events
    • Email Alerts
  • Company Information
  • Financial Information
  • Stock Data
  • Corporate Governance
  • SEDAR
  • Quick Links
  • Email Alerts
  • Tear Sheet
  • Contacts
  • RSS News Feed

Press Releases

  • All News
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009
  • 2008
  • 2007

Ceapro Inc. Reports 2023 Third Quarter and Nine-Month Financial Results and Operational Highlights

November 29, 2023

Ceapro Inc. Initiates Phase 1-2a Study Assessing Its Flagship Product Avenanthramides for Potential Applications in Inflammation Based Diseases

November 27, 2023

Ceapro Inc. Enters into Technical Collaboration with NATEX Prozesstechnologie GmbH and Provides Update on the Scale-Up Project for its Patented Pressurized Gas eXpanded (PGX) Technology

November 7, 2023

Ceapro Inc. Reports 2023 Second Quarter and Six-Month Financial Results and Provides Corporate Update

August 29, 2023

Ceapro Extends Exclusive International Supply and Distribution Agreement with Leading Global Provider of Active Ingredients, Symrise

August 25, 2023

Ceapro Announces Next Phase of Research Collaboration with the Angiogenesis Foundation

July 18, 2023

Ceapro to Participate in the Virtual Investor Summer Spotlight Series

July 5, 2023

Ceapro Announces Results of 2023 Shareholders’ Meeting

June 7, 2023

Ceapro Inc. Reports Financial Results for First Quarter 2023 and Provides Corporate Update

May 25, 2023

Ceapro Inc. Presents Encouraging Results from Research Collaboration Study with McMaster University Evaluating PGX-Processed Yeast Beta Glucan for Interstitial Lung Diseases

May 23, 2023

RSS
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...26
  • Next »

Sign up for email ALERTS Be the first to receive news and updates on Ceapro. Sign Up

  • © 2023 Ceapro Inc.
  • Privacy Policy
  • Disclaimer
  • Sitemap